Cullen Frost Bankers Inc. Sells 88 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Cullen Frost Bankers Inc. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,550 shares of the company’s stock after selling 88 shares during the period. Cullen Frost Bankers Inc.’s holdings in IDEXX Laboratories were worth $1,970,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of IDXX. OFI Invest Asset Management purchased a new stake in IDEXX Laboratories during the third quarter valued at $25,000. Valley National Advisers Inc. raised its stake in IDEXX Laboratories by 84.6% during the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares in the last quarter. Geo Capital Gestora de Recursos Ltd purchased a new stake in IDEXX Laboratories during the third quarter valued at $28,000. Covestor Ltd raised its stake in IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after purchasing an additional 28 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in IDEXX Laboratories by 108.6% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 73 shares of the company’s stock valued at $32,000 after purchasing an additional 38 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.7 %

NASDAQ IDXX opened at $487.07 on Thursday. The company’s 50-day moving average price is $519.60 and its 200-day moving average price is $514.34. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. The stock has a market cap of $40.23 billion, a PE ratio of 47.15, a PEG ratio of 3.78 and a beta of 1.27. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The company had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. During the same period in the prior year, the business earned $2.05 EPS. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.05 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on IDXX. Barclays decreased their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. The Goldman Sachs Group boosted their price objective on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. boosted their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Finally, Piper Sandler cut shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective on the stock. in a research report on Tuesday, January 30th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $580.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.